Acquisition of Landmark Autologous Cell Therapy Portfolio and Manufacturing Centers in U.S. and Europe Positions Aastrom as a Global Leader in Regenerative Medicine

Company Milestone Achieved by Initiating Treatments in Heart Failure Patients With Dilated Cardiomyopathy -- a Severe Chronic Disease of the Heart

Top Cell Biologists and Cardiovascular Disease Experts to Provide Scientific and Clinical Development Counsel

ANN ARBOR, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the initiation of commercial sales of bone marrow by Marrow

ANN ARBOR, Mich., June 15, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, will hold an investor conference call and slide presentation on Monday, June 16,

Aastrom Announces Its Fourth Quarter and Fiscal Year End Investor Conference Call Ann Arbor, MI, September 7 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fourth Quarter and Fiscal Year End FY2005 Investor Conference Call When: Thursday, September

Essential Manufacturing Steps Completed in Preparation for Phase 3 CLI Program

ANN ARBOR, Mich., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences (Nasdaq:ASTM) announced today that its board of directors has approved a one-for-eight reverse stock split of the company's common stock effective on February 18, 2010. The company has filed an amendment to its articles of

ANN ARBOR, Mich., March 21, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company shareholders approved amendments to the company's

Results presented today at 15th Annual Heart Failure Society of America Scientific Meeting Aastrom also announces results of six-month interim analysis of DCM patients treated with ixmyelocel-T via catheter administration. ANN ARBOR, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences,